Assessing Continuous Glucose Monitoring in Asian Americans with Type 2 Diabetes
A Pilot Clinical Trial to Assess Feasibility, Facilitators and Barriers of Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
NA · Joslin Diabetes Center · NCT05826678
This study is testing if using continuous glucose monitors can help Asian Americans with type 2 diabetes manage their health better compared to traditional fingerstick methods.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Joslin Diabetes Center (other) |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT05826678 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of continuous glucose monitors (CGM) in improving health outcomes for Asian Americans with type 2 diabetes. Participants will be divided into two groups: one using CGM and the other using traditional fingerstick monitoring. The study aims to assess the feasibility of CGM, its impact on quality of life, and how social factors influence its use. The research addresses significant health disparities faced by Asian Americans in diabetes care and management.
Who should consider this trial
Good fit: Ideal candidates are Chinese Americans aged 40 and older, who are first-generation immigrants, clinically diagnosed with type 2 diabetes, and CGM-naïve.
Not a fit: Patients with known cognitive impairments, language barriers, or those who are critically ill may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diabetes management and health outcomes for Asian Americans.
How similar studies have performed: Other studies have shown success with continuous glucose monitoring in diverse populations, but this specific focus on Asian Americans is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chinese Americans 40 years and older who are 1st generation immigrants, currently residing in the US, and clinically diagnosed with T2D. * CGM-naïve * HbA1c \>7.5% within 3 months of study commencement. * Participants should also possess a smartphone, as this is needed in order to facilitate the collection of CGM data by the study team as well as homogenize CGM usage education. Exclusion Criteria: * Known diagnosis of dysfunction/dementia or learning disabilities * Not fluent in either English or Chinese * Currently undergoing or planning to undergo diathermy or high-frequency heat treatments in whom CGM use may be contraindicated * Inability to travel due to frailty or health reasons * Lack of internet access * Critically ill populations, including those on dialysis * Vulnerable populations (prisoners and women who are pregnant or planning to be pregnant during the time of study)
Where this trial is running
Boston, Massachusetts
- Joslin Diabetes Center — Boston, Massachusetts, United States (RECRUITING)
Study contacts
- Principal investigator: George King, MD — Joslin Diabetes Center
- Study coordinator: Hetal Shah, MD, MPH
- Email: hetal.shah@joslin.harvard.edu
- Phone: 617-309-4343
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Diabetes Mellitus, Type 2, Continuous Glucose Monitoring, Health Disparity